DeepMed Research

SWOG

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1956-01-01

Employees: 101

Market Cap: -

Website: http://www.swog.org

Clinical Trials

S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2009-05-12

Last Posted Date: 2018-06-28

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 91

Registration Number: NCT00898183

S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911

Completed

Conditions: Lymphoma

First Posted Date: 2009-05-12

Last Posted Date: 2017-02-28

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 180

Registration Number: NCT00896922

S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia

Completed

Conditions: Leukemia

First Posted Date: 2009-05-12

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 132

Registration Number: NCT00899743

SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897

Completed

Conditions: Breast Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2017-02-17

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1577

Registration Number: NCT00896623

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2009-04-02

Last Posted Date: 2013-04-10

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00873808

Locations: 🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Completed

Conditions: Multiple Myeloma
Unspecified Adult Solid Tumor, Protocol Specific
Breast Cancer
Metastatic Cancer
Prostate Cancer
Lung Cancer
Plasma Cell Neoplasm

Interventions: Procedure: assessment of therapy complications

First Posted Date: 2009-04-02

Last Posted Date: 2019-07-05

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 3571

Registration Number: NCT00874211

Locations: 🇺🇸
Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States
🇺🇸
CCOP - Columbus, Columbus, Ohio, United States
🇺🇸
Grant Medical Center Cancer Care, Columbus, Ohio, United States

and more 448 locations

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: docetaxel
Drug: vandetanib

First Posted Date: 2009-04-01

Last Posted Date: 2016-12-19

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 129

Registration Number: NCT00872989

Locations: 🇺🇸
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸
Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States
🇺🇸
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States

and more 134 locations

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: pegfilgrastim
Biological: bevacizumab
Drug: cyclophosphamide
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Drug: doxorubicin hydrochloride

First Posted Date: 2009-03-05

Last Posted Date: 2017-06-27

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 215

Registration Number: NCT00856492

Locations: 🇺🇸
Illinois CancerCare - Havana, Havana, Illinois, United States
🇺🇸
Illinois CancerCare - Macomb, Macomb, Illinois, United States
🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States

and more 362 locations

S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: idarubicin
Drug: pravastatin sodium

First Posted Date: 2009-02-10

Last Posted Date: 2023-05-03

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 115

Registration Number: NCT00840177

Locations: 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Genesee Hematology Oncology PC, Flint, Michigan, United States
🇺🇸
Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States

and more 182 locations

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma
Nonneoplastic Condition

Interventions: Biological: bleomycin sulfate
Drug: BEACOPP regimen
Biological: filgrastim
Drug: ABVD regimen
Drug: cyclophosphamide
Drug: dacarbazine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: vinblastine sulfate
Drug: prednisone
Drug: procarbazine hydrochloride
Drug: vincristine sulfate

First Posted Date: 2009-01-14

Last Posted Date: 2022-08-18

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 371

Registration Number: NCT00822120

Locations: 🇺🇸
Kaiser Foundation Hospital - San Rafael, San Rafael, California, United States
🇺🇸
Illinois CancerCare - Macomb, Macomb, Illinois, United States
🇺🇸
Saint Michael's Hospital Cancer Center, Stevens Point, Wisconsin, United States

and more 419 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy